tiprankstipranks
Advertisement
Advertisement

IMNM Stock Latest News

Immunome announces submission of NDA for varegacestat in desmoid tumors
The FlyImmunome announces submission of NDA for varegacestat in desmoid tumors
1d ago
IMNM
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
PremiumThe Fly
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
23d ago
GILD
IMNM
Immunome: Best-in-Class Varegacestat Data and Deep ADC Pipeline Support Buy Rating and Favorable Risk‑Reward
PremiumRatings
Immunome: Best-in-Class Varegacestat Data and Deep ADC Pipeline Support Buy Rating and Favorable Risk‑Reward
2M ago
IMNM
Immunome price target lowered to $30 from $32 at Lake Street
PremiumThe Fly
Immunome price target lowered to $30 from $32 at Lake Street
2M ago
IMNM
Immunome price target raised to $36 from $33 at Craig-Hallum
PremiumThe Fly
Immunome price target raised to $36 from $33 at Craig-Hallum
2M ago
IMNM
Immunome price target lowered to $30 from $33 at Stephens
PremiumThe FlyImmunome price target lowered to $30 from $33 at Stephens
2M ago
IMNM
Immunome price target raised to $39 from $35 at JPMorgan
Premium
The Fly
Immunome price target raised to $39 from $35 at JPMorgan
2M ago
IMNM
Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
Premium
Ratings
Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform
2M ago
IMNM
Immunome reports FY25 EPS ($2.43), consensus ($2.21)
PremiumThe Fly
Immunome reports FY25 EPS ($2.43), consensus ($2.21)
2M ago
IMNM
Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target
PremiumRatings
Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target
2M ago
IMNM
Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls
3M ago
ON
ADI
Immunome: Differentiated Oncology Portfolio and ADC Platform Underpin Buy Rating and $40 Price Target
PremiumRatings
Immunome: Differentiated Oncology Portfolio and ADC Platform Underpin Buy Rating and $40 Price Target
3M ago
IMNM
Immunome initiated with a Buy at H.C. Wainwright
PremiumThe FlyImmunome initiated with a Buy at H.C. Wainwright
3M ago
IMNM
Immunome Announces Follow-On Public Offering Pricing
Premium
Company Announcements
Immunome Announces Follow-On Public Offering Pricing
4M ago
8K
IMNM
Midday Fly By: Warner Bros. urges investors to reject Paramount bid
Premium
The Fly
Midday Fly By: Warner Bros. urges investors to reject Paramount bid
4M ago
PG
ABM
Immunome falls -7.2%
PremiumThe Fly
Immunome falls -7.2%
4M ago
IMNM
Immunome 18.625M share Spot Secondary priced at $21.50
PremiumThe Fly
Immunome 18.625M share Spot Secondary priced at $21.50
4M ago
IMNM
Immunome price target raised to $32 from $22 at Lake Street
PremiumThe Fly
Immunome price target raised to $32 from $22 at Lake Street
5M ago
IMNM
Immunome price target raised to $40 from $18 at Evercore ISI
PremiumThe Fly
Immunome price target raised to $40 from $18 at Evercore ISI
5M ago
IMNM
Immunome price target raised to $35 from $25 at Guggenheim
PremiumThe FlyImmunome price target raised to $35 from $25 at Guggenheim
5M ago
IMNM
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
5M ago
IMNM
KYTX
Immunome offers to sell $400M in common stock
Premium
The Fly
Immunome offers to sell $400M in common stock
5M ago
IMNM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >